Revance Therapeutics (NASDAQ:RVNC) posted its quarterly earnings data on Sunday. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.16) by ($0.08), MarketWatch Earnings reports. Revance Therapeutics had a negative return on equity of 85.72% and a negative net margin of 5,818.87%.
NASDAQ RVNC opened at $26.20 on Tuesday. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -5.86 and a beta of 1.42. Revance Therapeutics has a twelve month low of $11.78 and a twelve month high of $34.62. The business’s fifty day moving average is $28.31 and its 200 day moving average is $26.92. The company has a quick ratio of 7.01, a current ratio of 7.07 and a debt-to-equity ratio of 0.48.
A number of equities research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price (up previously from $33.00) on shares of Revance Therapeutics in a report on Tuesday. Needham & Company LLC raised their target price on Revance Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a report on Friday, January 8th. Zacks Investment Research downgraded Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, February 12th. Barclays raised their target price on Revance Therapeutics from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Monday, October 26th. Finally, Mizuho raised their target price on Revance Therapeutics from $30.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $32.88.
In other Revance Therapeutics news, insider Aubrey Rankin sold 33,119 shares of Revance Therapeutics stock in a transaction dated Monday, November 30th. The stock was sold at an average price of $23.85, for a total transaction of $789,888.15. Following the transaction, the insider now directly owns 67,871 shares of the company’s stock, valued at approximately $1,618,723.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.80% of the stock is currently owned by insiders.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine.
See Also: How dollar cost averaging works
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.